Close

GAP50

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Virus-specific T cell populations have been implicated in allo-recognition. The subdominant T cell receptor JL12 recognizes both HLA-B*0801 presenting the Epstein-Barr virus-derived peptide FLRGRAYGL and also HLA-B*3501 presenting the cytochrome p450 self peptide KPIVVLHGY. This cross-reactivity could promote the rejection of HLA-B*3501-positive cells in Epstein-Barr virus-exposed HLA-B*0801 recipients. LC13, the dominant TCR against the HLA-B*0801:FLRGRAYGL complex, fails to recognize HLA-B*3501:KPIVVLHGY.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC0420 Mouse anti-GAP50 T cell receptor (NB1), pCDTCR1 Plasmodium berghei NB1 Mouse GAP50 40-48 H2-Dᵇ Lentiviral vector   Add to Cart   Datasheet
TCR-YC0421 Mouse anti-GAP50 T cell receptor (NB1 V58A), pCDTCR1 Plasmodium berghei NB1 V58A Mouse GAP50 40-48 H2-Dᵇ Lentiviral vector   Add to Cart   Datasheet
TCR-YC0422 Mouse anti-GAP50 T cell receptor (NB1 Y57A), pCDTCR1 Plasmodium berghei NB1 Y57A Mouse GAP50 40-48 H2-Dᵇ Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.